Masakiyo Sakaguchi

USPTO Granted Patents = 9 (Patent Applications = 7)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 17(Granted Patents)

Company Filing History:

5. 3 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11858984 - Anti-S100A8/A9 antibody and use thereof (2024-01-02),

2. 9696321 - Therapeutic agent, method of treatment and method for predicting the severity of systemic inflammatory response syndrome (SIRS), diseases caused or accompanied by neutrophil activation (2017-07-04),

3. 9504731 - Therapeutic agent, treatment method and inspection method for diseases caused by activation of neutrophils (2016-11-29),

4. 9493776 - System for increasing gene expression and vector comprising the system (2016-11-15),

5. 9475865 - Direct administration of REIC/Dkk-3 to mesothelioma (2016-10-25),

6. 9222107 - REIC-expressing adenovirus vector (2015-12-29),

7. 8658612 - Therapeutic agent for malignant mesothelioma and immunostimulant (2014-02-25),

8. 8658611 - Apoptosis-inducing agent for prostate cancer cells (2014-02-25),

9. 8618273 - Partial fragment of REIC/Dkk-3 gene and cancer therapeutic agent comprising the same (2013-12-31),

Title: Masakiyo Sakaguchi: Innovator in Cancer and Inflammatory Disease Research

Introduction

Masakiyo Sakaguchi is a prominent inventor based in Okayama, Japan. He has made significant contributions to the fields of cancer research and inflammatory diseases. With a total of nine patents to his name, his work focuses on innovative therapeutic agents and methods for treatment.

Latest Patents

One of Sakaguchi's latest patents is the development of an anti-S100A8/A9 antibody and its use in suppressing cancer metastasis. This invention provides a pharmaceutical composition that effectively acts on inflammatory diseases. The composition contains an antibody or an antibody fragment that binds to the S100A8/A9 heterodimer, blocking its interaction with specific receptors. This action significantly suppresses cancer metastasis both in vitro and in vivo, while also alleviating inflammation. Another notable patent involves a neutrophil activation regulator comprising a histidine-rich glycoprotein (HRG) for treating systemic inflammatory response syndrome (SIRS) and related diseases. This invention includes methods for predicting the severity of SIRS and the survival of affected subjects based on blood levels of HRG.

Career Highlights

Sakaguchi has worked at Okayama University, where he has contributed to various research projects and innovations. His expertise in the field has led to the development of groundbreaking therapeutic agents that address critical health issues.

Collaborations

Throughout his career, Sakaguchi has collaborated with notable colleagues, including Hiromi Kumon and Nam-Ho Huh. These partnerships have enhanced his research and contributed to the advancement of medical science.

Conclusion

Masakiyo Sakaguchi's work exemplifies the impact of innovative research in combating cancer and inflammatory diseases. His patents reflect a commitment to improving therapeutic options and patient outcomes.

This text is generated by artificial intelligence and may not be accurate.